Article
Gastroenterology & Hepatology
Edward V. Loftus, Severine Vermeire, Brian G. Feagan, Franck-Olivier Le Brun, Alessandra Oortwijn, Ulrik Moerch, William J. Sandborn, Toshifumi Hibi
Summary: In patients with ulcerative colitis, the study found that 200 mg of filgotinib can reduce the use of corticosteroids and maintain corticosteroid-free clinical remission. Moreover, compared to other medications, filgotinib demonstrated better outcomes in patients who had not previously used biologic agents.
JOURNAL OF CROHNS & COLITIS
(2023)
Review
Gastroenterology & Hepatology
Akshita Gupta, Amy Yu, Laurent Peyrin-Biroulet, Ashwin N. Ananthakrishnan
Summary: In patients with UC in endoscopic remission, persistent histologic activity is associated with higher rates of relapse. Greater degree of normalization may have a stronger impact. Individual histologic features such as basal plasmacytosis, neutrophilic infiltrations, mucin depletion, and crypt architectural irregularities predicted relapse.
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY
(2021)
Article
Gastroenterology & Hepatology
Andreas Blesl, Philipp Wurm, Silvio Waschina, Hans Peter Groechenig, Gottfried Novacek, Christian Primas, Walter Reinisch, Maximilian Kutschera, Constanze Illiasch, Barbara Hennlich, Pius Steiner, Robert Koch, Wolfgang Tillinger, Thomas Haas, Gerhard Reicht, Andreas Mayer, Othmar Ludwiczek, Wolfgang Miehsler, Karin Steidl, Lukas Binder, Simon Reider, Christina Watschinger, Stefan Fuerst, Patrizia Kump, Alexander Moschen, Konrad Aden, Gregor Gorkiewicz, Christoph Hoegenauer, Austrian IBD Study Grp ATISG
Summary: This study examined the association between fecal microbial composition and response to systemic corticosteroids in patients with active ulcerative colitis. It found that baseline microbial diversity and composition could not predict response to corticosteroids, but responders had significant changes in microbial diversity and composition after 4 weeks of treatment.
INFLAMMATORY BOWEL DISEASES
(2023)
Article
Microbiology
Hiroaki Kitae, Tomohisa Takagi, Yuji Naito, Ryo Inoue, Yuka Azuma, Takashi Torii, Katsura Mizushima, Toshifumi Doi, Ken Inoue, Osamu Dohi, Naohisa Yoshida, Kazuhiro Kamada, Kazuhiko Uchiyama, Takeshi Ishikawa, Hideyuki Konishi, Yoshito Itoh
Summary: This study analyzed the fecal microbiota of patients with quiescent ulcerative colitis (qUC) to identify the relapse-associated microbiota. The study found significant differences in the fecal microbiota between healthy controls and qUC patients, and differences in microbial community variation between sustained remission and relapsed patients. The study also identified three genera associated with relapse and found that different clusters based on these genera had different subsequent clinical courses and activated different metabolic pathways.
Article
Gastroenterology & Hepatology
Yiyoung Kwon, Eun Sil Kim, Yon Ho Choe, Mi Jin Kim
Summary: After the introduction of infliximab, the relapse rate has decreased and the steroid-free period has increased in pediatric ulcerative colitis patients. The clinical course showed a different pattern from the IBSEN study.
WORLD JOURNAL OF GASTROENTEROLOGY
(2022)
Article
Gastroenterology & Hepatology
Hala El-Zimaity, Seth R. Shaffer, Robert H. Riddell, Rish K. Pai, Charles N. Bernstein
Summary: This study investigates the histological features in ulcerative colitis patients in endoscopic remission. The study finds that the presence of ulcers, especially in the left colon, is highly predictive of relapse. Increased plasma cells in the basal 20% of the lamina propria and eosinophils in the left colon are the variables most predictive of relapse in the absence of acute inflammation or ulcers.
JOURNAL OF CROHNS & COLITIS
(2023)
Article
Gastroenterology & Hepatology
Mao Matsubayashi, Taku Kobayashi, Shinji Okabayashi, Masaru Nakano, Shintaro Sagami, Ryo Ozaki, Hiroki Kiyohara, Hiromu Morikubo, Kunio Asonuma, Yusuke Miyatani, Shin Maeda, Toshifumi Hibi
Summary: CSUC score can predict relapse within one year in UC patients during clinical remission, especially when used 6 months after induction treatment.
JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY
(2021)
Article
Medicine, General & Internal
Andreas Blesl, Andrea Borenich, Hans Peter Groechenig, Gottfried Novacek, Christian Primas, Walter Reinisch, Maximilian Kutschera, Constanze Illiasch, Barbara Hennlich, Pius Steiner, Robert Koch, Wolfgang Tillinger, Thomas Haas, Gerhard Reicht, Andreas Mayer, Othmar Ludwiczek, Wolfgang Miehsler, Karin Steidl, Lukas Binder, Franziska Baumann-Durchschein, Stefan Fuerst, Simon Reider, Christina Watschinger, Heimo Wenzl, Alexander Moschen, Andrea Berghold, Christoph Hoegenauer
Summary: The effectiveness of corticosteroids in ulcerative colitis patients needs to be reevaluated. This study found that 73% of patients achieved clinical response after 4 weeks, and 68% achieved combined response. Disease activity did not affect short-term treatment response but increased the risk of steroid dependence. Biologic-naive patients responded better than biologic-experienced patients.
JOURNAL OF CLINICAL MEDICINE
(2023)
Article
Gastroenterology & Hepatology
Shomron Ben-Horin, Ofir Har-Noy, Konstantinos H. Katsanos, Xavier Roblin, Minhu Chen, Xiang Gao, Doron Schwartz, Jae Hee Cheon, Monica Cesarini, Daniela Bojic, Marijana Protic, Angeliki Theodoropoulou, Heba Abu-Kaf, Tal Engel, Jian Tang, Pauline Veyrard, Xiaoqing Lin, Ren Mao, Dimitrios Christodoulou, Konstantinos Karmiris, Tamara Knezevic-Ivanovski
Summary: In this randomized controlled trial, the combination of mesalamine with corticosteroids did not show superior efficacy compared to corticosteroids alone in hospitalized patients with acute severe ulcerative colitis (ASUC). However, there was a potential indication that the need for biologics was reduced in the mesalamine group within 90 days.
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY
(2022)
Article
Immunology
Yiyoung Kwon, Yoon Zi Kim, Yon Ho Choe, Mi Jin Kim
Summary: This study found that patients with high monocyte counts at the time of discontinuation were more likely to experience relapse after stopping biologics. The monocyte percentage can be used to predict the risk of relapse within 6 months after discontinuation.
FRONTIERS IN IMMUNOLOGY
(2022)
Article
Cardiac & Cardiovascular Systems
Xuhan Liu, Xia Peng, Chunyan Rong, Weihua Zhang
Summary: Patients with ulcerative colitis are prone to VTE and the use of corticosteroids increases the risk of thrombus. Anticoagulation strategy for patients with ulcerative colitis after gastrointestinal bleeding is a topic for discussion.
FRONTIERS IN CARDIOVASCULAR MEDICINE
(2022)
Article
Gastroenterology & Hepatology
Arash Assadsangabi, Caroline A. Evans, Bernard M. Corfe, Alan J. Lobo
Summary: This study aimed to investigate whether specific proteins (biomarkers) can predict disease relapse in patients with Ulcerative Colitis (UC). Rectal samples were collected from UC patients in remission and from healthy individuals. The patients were categorized into early relapsers and non-relapsers. Proteomics analysis revealed that TRX and IGHA1 proteins were significantly higher in early relapsers. These proteins could potentially be used as markers to identify UC patients at risk of early relapse, allowing for more effective monitoring and treatment decisions.
INFLAMMATORY BOWEL DISEASES
(2023)
Article
Medicine, General & Internal
Beatriz Sicilia, Lara Arias, Gadea Hontoria, Nieves Garcia, Ester Badia, Fernando Gomollon
Summary: This study evaluated the effectiveness of corticosteroids in immunosuppressed patients with inflammatory bowel disease (IBD) and found that 23% of patients needed at least one course of steroids, with CD patients more likely to escalate to biologics or surgery. Patients with CD displaying fibrostenotic (B2) and fistulizing (B3) behaviors were at a higher risk for requiring steroids after immunosuppressive treatment.
FRONTIERS IN MEDICINE
(2021)
Article
Pediatrics
Yiyoung Kwon, Eun Sil Kim, Yon Ho Choe, Mi Jin Kim
Summary: In this study, pediatric UC patients with EIMs showed higher disease severity and often presented with upper gastrointestinal tract involvement. Despite treatment for EIMs, new occurrences were observed repetitively. The cumulative drug demand for treatment increased steadily over time, and frequent relapses occurred despite combinatory use of therapeutic drugs.
FRONTIERS IN PEDIATRICS
(2022)
Article
Gastroenterology & Hepatology
Natsuki Ishida, Shunya Onoue, Takahiro Miyazu, Satoshi Tamura, Shinya Tani, Mihoko Yamade, Moriya Iwaizumi, Yasushi Hamaya, Satoshi Osawa, Takahisa Furuta, Ken Sugimoto
Summary: This study established a cut-off value of 9.8 for the UCCIS score to predict clinical relapse in patients with ulcerative colitis, and identified optimal cut-off values of 10.2 for UCCIS and 1 for S-MES for predicting relapse within 5 years.
INTERNATIONAL JOURNAL OF COLORECTAL DISEASE
(2021)